Maat Pharma (MAAT.PA) Action Cours

Maat Pharma SA generates revenue through its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform, which evaluates drug candidates and identifies biomarkers for microbiome-related conditions. The company focuses on developing patient-specific biotherapeutics targeting Gut Microbiota alteration (Dysbiosis) in serious medical conditions. Clinical-stage microbiome therapeutics are the core product, with the platform supporting the determination of new disease targets and drug candidate evaluation. The primary buyers are healthcare providers and research institutions seeking advanced microbiome-based treatments for dysbiosis-related disorders. The company's MMRB platform is central to its business model, enabling the analysis of microbiome data to develop tailored therapies. Maat Pharma SA's clinical-stage focus means it is still in the development phase, with revenue likely derived from partnerships or licensing agreements rather than direct sales. The target market includes patients with serious medical conditions requiring microbiome restoration, though the company does not sell directly to consumers. Maat Pharma SA's business model relies on its proprietary MMRB platform to advance microbiome therapeutics from discovery to clinical application. The company's specialization in patient-specific biotherapeutics for dysbiosis positions it within the niche of microbiome-based treatments. The firm's clinical-stage status indicates that revenue streams are currently limited to potential future partnerships, with no indication of direct product sales to end-users.